Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and ...

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest’s Substack. In ...

Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

A large portion of this downturn can be ascribed to the company’s less-than-expected performance, especially concerning its existing blockbuster treatment, Eylea. To add to Regeneron’s ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: CRISPR Therapeutics (NASDAQ: CRSP) and Regeneron Pharmaceuticals (NASDAQ: REGN).